Address: Kavaklıdere Mahallesi
Akay Caddesi No:5
Çankaya/ANKARA 06640,Turkey
Tel: (+90 312) 413 89 00
Web: http://www.invest.gov.tr/en-US/Pages/Home.aspx
The Investment Support and Promotion Agency of Turkey (ISPAT) was established under the auspices of the Prime Ministry in 2006. ISPAT is the official organisation for promoting Turkey’s investment opportunities to the global business community and providing assistance to investors before, during and after their entry into Turkey. ISPAT serves as a reference point for international investors and as a point of contact for all institutions engaged in promoting and attracting investments at national, regional and local levels. It works on a fully confidential basis and combines a private sector approach with the backing of all governmental bodies.
ISPAT’s free-of-charge services include, but are not limited to, providing market information and analyses, site selection, B2B meetings, coordination with relevant governmental institutions, and facilitating legal procedures and applications, such as establishing business operations, incentive applications, obtaining licenses and work permits.
Currently, what are the main priorities and goals of ISPAT related to the Healthcare and Pharmaceuticals sector, and what are the overall strategies designed to achieve these objectives? As an…
A roundup of the biggest pharma and healthcare stories from Turkey including the investigation of 19 pharma companies by the country’s competition watchdog; Gen Pharma Caucasus Manufacturing’s new plant in…
A roundup of the latest pharma and healthcare news from Turkey including Omya’s new Turkish manufacturing site, Santa Farma’s fourth EU-GMP certification and the collaboration agreement between BioNTech and Turkey’s…
A roundup of the latest pharma and healthcare news from Turkey including Roche Turkey’s digital platform for HCPs and patients, big pharma’s aid to earthquake victims, the Scientific and Technological…
The Middle East and Africa (MEA), the fifth-largest regional pharma market in the world, is rapidly becoming a pharmaceutical powerhouse with both global and local firms taking advantage of the…
After its best financial year to date – posting revenues of USD 27.3 billion in 2021 – Gilead has said yes to localization in Turkey. The California-based company, known for…
Turkey’s pharma market, the 18th largest in the world and valued at USD 7 Billion in 2020, has seen steady growth over the past few years due to favorable healthcare…
With an already well-established manufacturing industry for pharmaceuticals, Turkey has been aiming to move with global trends and invest in biologics production, specifically in biosimilars. The share of biotechnological…
Becoming the clinical trials country leader in the region has been set as a primary goal for Turkey’s pharma industry to achieve global competitiveness. The government’s strategy is to increase…
Few Turkish companies are experiencing such a transformational moment as GEN. In 2021 alone, the Ankara-based organization made its public debut on the Istanbul Stock Exchange and signed an exclusive…
When the Turkish Ministry of Health implemented its strategy to transition from import pharmaceuticals to manufacturing them at home in 2016, the local industry leveraged the situation to invest in…
As an upper-middle-income country with an emerging economy, Turkey could not invest billions in COVID-19 vaccine R&D, but a strong research ecosystem and willing industry allowed it to kickstart multiple…
Overseeing healthcare for a population of over 80 million, Turkey’s Ministry of Health was put under the spotlight during the COVID-19 pandemic. Here, we highlight four of the hot-button items…
See our Cookie Privacy Policy Here
